



2721 13 AUG 20 P3:46

August 16, 2013

**BY OVERNIGHT MAIL**

Division of Dockets Management (HFA-305)  
U.S. Food and Drug Administration  
5630 Fishers Lane  
Room 1061  
Rockville, MD 20852

**CITIZEN PETITION**

Dear Sir or Madam,

The undersigned submits this petition in quadruplicate pursuant to 21 C.F.R. §§ 10.30 and 314.161, requesting the Commissioner of the Food and Drug Administration to provide a determination whether a listed drug has been withheld from sale for safety or effectiveness reasons, as outlined below.

**A. Action Requested**

The petitioner requests that the Commissioner of the Food and Drug Administration (FDA) determine that SUBUTEX® (buprenorphine hydrochloride) Sublingual Tablets, EQ. 2 mg and 8 mg Base were not voluntarily withdrawn for safety or efficacy reasons.

**B. Statement of Grounds**

1. The above-referenced drug products were initially approved under NDA 20-732 on October 8, 2002. (See attached, Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations)

2. At the time of this submission, there is no evidence that the NDA holder is currently marketing SUBUTEX® (buprenorphine hydrochloride) Sublingual Tablets, EQ. 2 mg and 8 mg Base.

3. An abbreviated new drug application (ANDA) seeking approval of a generic formulation of a discontinued reference listed drug must be accompanied by a Citizen Petition for FDA's determination that the discontinued reference listed drug was not voluntarily withdrawn for safety or effectiveness reasons. 21 C.F.R. §§ 314.122, 314.161.

Actavis Regulatory Affairs Department

200 Elmora Avenue  
Elizabeth, NJ 07207

908 659 2527  
908 659 2250

RegulatoryAffairsUS@actavis.com

FDA-2013-P-1055

2013-7203  
CP



CITIZEN PETITION

ANDA # 090819

Buprenorphine Hydrochloride Sublingual Tablets, Eq. 2 mg and 8 mg Base

Page 2 of 2

---

4. Because there is no apparent commercial distribution of SUBUTEX® (buprenorphine hydrochloride) Sublingual Tablets, EQ. 2 mg and 8 mg Base, it is requested that the FDA determine whether the applicant holder's decision to not market the drug products, as approved under NDA 20-732, was for reasons of safety or effectiveness.

5. Should the NDA holder commence marketing of SUBUTEX® (buprenorphine hydrochloride) Sublingual Tablets, EQ. 2 mg and 8 mg Base after submission of this petition but before an FDA response, Actavis will consider this petition moot and take appropriate action to request its withdrawal.

**C. Environmental Impact**

Petitioner claims a categorical exclusion from the requirement of an environmental assessment or environmental impact statement pursuant to 21 C.F.R. § 25.31.

**D. Economic Impact**

Pursuant to 21 C.F.R. § 10.30(b), economic impact information is to be submitted only when requested by the Commissioner following review of this petition.

**E. Certification**

The undersigned certifies that to the best knowledge and belief of the undersigned, this Citizen Petition includes all information and views upon which the petition relies, and includes representative data and information known to the petitioner which are unfavorable to the petition.

Respectfully submitted,

Actavis Elizabeth LLC.



---

Janak Jadeja, R.Ph.  
Director, Regulatory Affairs  
Actavis Elizabeth LLC.  
200 Elmora Ave  
Elizabeth, NJ 07207  
Telephone: (908) 659-2595  
Facsimile: (908) 659-2250



From: (908) 659-2527  
 Carla Hedrick  
 ACTAVIS  
 200 Elmora Avenue

Elizabeth, NJ 07207

Origin ID: ANNA



J13201306280326

SHIP TO: (301) 827-6860

BILL SENDER

**U.S. Food and Drugs Administration**  
**Division of Dockets Management**  
 5630 Fishers Lane  
 Room 1061 (HFA-305)  
 ROCKVILLE, MD 20852

Ship Date: 16AUG13  
 ActWgt: 1.0 LB  
 CAD: 105112382/INET3430

Delivery Address Bar Code



Ref # CITIZEN PETITION  
 Invoice #  
 PO #  
 Dept #

MON - 19 AUG 8:00A  
 FIRST OVERNIGHT

TRK# 7964 8222 4845


0201

**X1 NSFA**

20852

MD-US

IAD



51AG109BB/1A9E

**After printing this label:**

1. Use the 'Print' button on this page to print your label to your laser or inkjet printer.
2. Fold the printed page along the horizontal line.
3. Place label in shipping pouch and affix it to your shipment so that the barcode portion of the label can be read and scanned.

**Warning:** Use only the printed original label for shipping. Using a photocopy of this label for shipping purposes is fraudulent and could result in additional billing charges, along with the cancellation of your FedEx account number. Use of this system constitutes your agreement to the service conditions in the current FedEx Service Guide, available on [fedex.com](http://fedex.com). FedEx will not be responsible for any claim in excess of \$100 per package, whether the result of loss, damage, delay, non-delivery, misdelivery, or misinformation, unless you declare a higher value, pay an additional charge, document your actual loss and file a timely claim. Limitations found in the current FedEx Service Guide apply. Your right to recover from FedEx for any loss, including intrinsic value of the package, loss of sales, income interest, profit, attorney's fees, costs, and other forms of damage whether direct, incidental, consequential, or special is limited to the greater of \$100 or the authorized declared value. Recovery cannot exceed actual documented loss. Maximum for items of extraordinary value is \$1,000, e.g. jewelry, precious metals, negotiable instruments and other items listed in our Service Guide. Written claims must be filed within strict time limits, see current FedEx Service Guide.